KannaLife Sciences, Inc.

21 articles about KannaLife Sciences, Inc.

• Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors

  9/17/2020

  Kannalife, Inc., a biopharmaceutical medicinal chemistry company specializing in the research and development of potent novel monotherapeutics, announced that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors.

• Kannalife, Inc. Receives Patent Grants in Additional European Territories

  8/25/2020

  Kannalife, Inc. announced that the Company has been issued patents in Austria, Luxembourg, Liechtenstein, and the Principality of Monaco for its patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”.

• Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors

  6/2/2020

  Kannalife, Inc., a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Company’s Board of Advisors.

• UPDATE – Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™

  4/1/2020

  Kannalife, Inc., a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office for its trademark application for the mark, “Atopidine”.

• Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™

  4/1/2020

  Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, “Atopidine”. The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl E

• Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders

  3/18/2020

  Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical med-chem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued Australian Patent AU2015204609B2 (the “Patent”) specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” This patent grant marks the seventh paten

• Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent

  2/18/2020

  Kannalife, Inc. announced that China has issued the Company, Chinese Patent CN106456573B specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” which further bolsters the Company’s global patent portfolio of cannabidiol -like molecules.

• Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN

  2/11/2020

  DOYLESTOWN, Pa., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTCQB: KLFE) (“Kannalife” or the “Company”), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA) . The study was performed by Kannalife and the Lewis Katz School of Medicine at Temple Universi

• Kannalife, Inc. Announces Filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders

  12/11/2019

  Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the filing of a new U.S. Patent for its proprietary and novel CBD-like molecules to treat radiation dermatitis (RD) and other skin disorders.

• Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol “KLFE”

  12/9/2019

  Kannalife, Inc. brings proven cannabinoid R&D to the public by officially commencing trading on the OTC Markets under the ticker symbol “KLFE.”

• Medical Marijuana, Inc. Portfolio Company Kannalife, Inc. Publishes New Research on CBD and Chemotherapy-Induced Peripheral Neuropathy

  5/23/2019

  Medical Marijuana, Inc. announced that the Company's portfolio company Kannalife, Inc., a biopharmaceutical company leading innovation in research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, published its research findings around Chemotherapy-Induced Peripheral Neuropathy in the Journal of Molecular Neuroscience.

• Medical Marijuana, Inc. Portfolio Company Kannalife Announces Completion of Name Change, Ticker Symbol Change

  1/17/2019

  Medical Marijuana, Inc., announced that its portfolio company Kannalife, Inc., has announced the company's name change from TYG Solutions Corp. to Kannalife, Inc. and the change of ticker symbol to "KLFE."

• 

  DEA Reclassifies GW Pharmaceuticals’ Epidiolex as a Schedule V Drug

  9/28/2018

  The DEA has reclassified GW Pharmaceutical’s cannabidiol epilepsy treatment Epidiolex as a Schedule V product, which will clear the way for commercialization within the next six weeks.

• Medical Marijuana, Inc. Portfolio Company Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions

  8/1/2018

  Medical Marijuana, Inc. announced that its portfolio company Kannalife Sciences, Inc. has completed a share exchange offer with TYG Solutions Corp.

• Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.

  8/1/2018

  Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange transaction with TYG Solutions Corp. (OTC: TYYG).

• 

  Cannabis-Based Drug Developers Are Hopeful as FDA Approves First Marijuana-based Seizure Treatment

  6/26/2018

  In a first of its kind ruling, the U.S. Food and Drug Administration approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

• KannaLife Sciences, Inc. Discusses Orphan Drug Opportunity For KLS-13019

  8/11/2015

• KannaLife Sciences, Inc. Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents

  8/6/2015

• KannaLife Sciences, Inc. Announces The Addition Of Dr. Bennet Omalu, Renowned Pathologist And Founder Of Chronic Traumatic Encephalopathy, To Its Scientific Advisory Board

  3/4/2015

• KannaLife Sciences, Inc. Files PCT Patent Application For Novel Treatments for Neurodegenerative Disorders

  1/23/2015